CO2020003486A2 - Composiciones tópicas para el tratamiento de la leishmaniasis cutánea - Google Patents

Composiciones tópicas para el tratamiento de la leishmaniasis cutánea

Info

Publication number
CO2020003486A2
CO2020003486A2 CONC2020/0003486A CO2020003486A CO2020003486A2 CO 2020003486 A2 CO2020003486 A2 CO 2020003486A2 CO 2020003486 A CO2020003486 A CO 2020003486A CO 2020003486 A2 CO2020003486 A2 CO 2020003486A2
Authority
CO
Colombia
Prior art keywords
treatment
composition
leishmaniasis
topical compositions
cutaneous leishmaniasis
Prior art date
Application number
CONC2020/0003486A
Other languages
English (en)
Inventor
Christian Auclair
Esther Fellous
Pape Patrice Le
Jorge E Kalil-Filho
Original Assignee
Ac Bioscience Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ac Bioscience Sa filed Critical Ac Bioscience Sa
Publication of CO2020003486A2 publication Critical patent/CO2020003486A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

RESUMEN La presente invención se refiere a una composición que comprende una combinación de un (halogenoacetamido)benzoato, un flavonol y un terpeno, y, como ejemplo, se refiere a una composición que comprende la combinación de 3-(2-cloroacetamido)benzoato de etilo, dihidroquercetina y bisabolol. Dicha composición es para uso en el tratamiento de la leishmaniasis, especialmente leishmaniasis cutánea o de la mucosa, la composición se aplica tópicamente para el tratamiento concomitante tanto de infección parasitaria como de inflamación de la piel del área infectada inducida por leishmaniasis.
CONC2020/0003486A 2017-09-04 2020-03-25 Composiciones tópicas para el tratamiento de la leishmaniasis cutánea CO2020003486A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17306143.3A EP3449906A1 (en) 2017-09-04 2017-09-04 Topical composition for use in treating cutaneous leishmaniasis
PCT/EP2018/073576 WO2019043212A1 (en) 2017-09-04 2018-09-03 TOPICAL COMPOSITIONS FOR THE TREATMENT OF SKIN LEHYMANIOSIS

Publications (1)

Publication Number Publication Date
CO2020003486A2 true CO2020003486A2 (es) 2020-07-31

Family

ID=59955514

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0003486A CO2020003486A2 (es) 2017-09-04 2020-03-25 Composiciones tópicas para el tratamiento de la leishmaniasis cutánea

Country Status (9)

Country Link
US (1) US11351146B2 (es)
EP (2) EP3449906A1 (es)
CN (1) CN111148516A (es)
BR (1) BR112020004337A2 (es)
CO (1) CO2020003486A2 (es)
IL (1) IL272999A (es)
MA (1) MA50066A (es)
MX (1) MX2020002358A (es)
WO (1) WO2019043212A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110996939A (zh) * 2017-08-03 2020-04-10 诺克斯生物公司 用于治疗皮肤利什曼病的方法的组合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2835253B1 (fr) * 2002-01-31 2008-02-01 Pape Patrice Le Composes, en particulier de derives urees ou esters de l'acide haloacetamidobenzoique et leur utilisation pour le traitement de maladies parasitaires

Also Published As

Publication number Publication date
EP3449906A1 (en) 2019-03-06
BR112020004337A2 (pt) 2020-09-08
EP3678656A1 (en) 2020-07-15
CN111148516A (zh) 2020-05-12
WO2019043212A1 (en) 2019-03-07
US11351146B2 (en) 2022-06-07
IL272999A (en) 2020-04-30
WO2019043212A8 (en) 2019-04-25
MX2020002358A (es) 2020-11-09
US20210059979A1 (en) 2021-03-04
MA50066A (fr) 2021-05-26

Similar Documents

Publication Publication Date Title
CL2019001079A1 (es) Métodos para usar indazol-3-carboxamidas y su uso como inhibidores de la vía de señalización de wnt/b-catenina.
BR112017012327A8 (pt) benzamidas substituídas por 1,3-tiazol-2-il.
NI201700135A (es) Derivados de ciclohexano sustituido con amido
CO6460708A2 (es) Composiciones borínicas
BR112015019657A2 (pt) composições tópicas e métodos de uso das mesmas
CO6351742A2 (es) Compuestos organicos para la cicatrizacion de heridas
AR097599A1 (es) Una composición que comprende extracto de guaçatonga y aroeira, su uso y un método para la prevención y/o tratamiento de señales causadas por el envejecimiento de la piel
CO6640220A2 (es) Composición de povidona yodada para uso tópico
AR077139A1 (es) Composiciones farmaceuticas utiles para tratar el vch
CL2011003327A1 (es) Composicion farmaceutica que comprende finafloxacina y un agente antiinflamatorio; uso en el tratamiento de infecciones oftalmicas, oticas o nasales.
CO2021003927A2 (es) Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular
BR112012013252A2 (pt) composição farmacêutica tópica, preservativo, composto, e, uso do mesmo
CL2021002263A1 (es) Compuestos antibacterianos (solicitud divisional 202001147)
CO7240418A2 (es) Apósito con una liberación prolongada de agentes activos
PE20180026A1 (es) Composicion topica curativa
AR112474A1 (es) Composición tópica semisólida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños crónicos de la piel
NI201900063A (es) Amidas aromáticas de ácido carboxílico
UY37577A (es) Dihidroimidazopiridindionas sustituidas
BR112015023878A2 (pt) composto, composição farmacêutica, e, uso de um composto
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
CL2019002514A1 (es) Composiciones cosméticas para el cuidado de la piel.
CL2015002466A1 (es) Formulaciones de compuestos orgánicos
CO2020003486A2 (es) Composiciones tópicas para el tratamiento de la leishmaniasis cutánea
AR084197A1 (es) Composicion para uso topico para el tratamiento de trastornos de la piel
UY35695A (es) Composicion para el tratamiento contra el envejecimiento de la piel